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The aim of this study was to determine the prevalence and the incidence of hepatitis B virus (HBV) among hae-
modialysis (HD) subjects and to evaluate whether testing for serological markers at the time of admission is suitable 
for HBV screening in this population. One hundred twenty-three patients belonging to two HD centres from São 
Paulo, Brazil, were tested prospectively. HBV DNA was detected by polymerase chain reaction (PCR) in each of the 
prospective subjects (n = 123) during one year. Additionally, all samples (n = 1,476) were analysed for HBV serologi-
cal markers. The prevalence of hepatitis B core antibody (anti-HBc), hepatitis B surface antigen (HBsAg) and HBV 
DNA were 34.1%, 15.4% and 8.1%, respectively, while the incidence was null. Fluctuation in HBV serology was ob-
served in one patient. Only 37.8% (17/45) of cases responded to the HBV vaccine. Our results suggest that employing 
more than one HBV marker and repeated follow-up evaluations may improve HBV screening in HD units.
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Hepatitis B virus (HBV) infection remains one of 
the most relevant diseases in humans. Chronic haemo-
dialysis (HD) patients especially are at higher risk for 
acquiring HBV infection because parenteral exposure 
is a major route of transmission. In Brazil, there are ap-
proximately 65,000 patients who receive HD treatment 
in 600 dialysis facilities, which include government, non-
profit and profit facilities; 2/3 of them are in hospitals and 
most of them are in the metropolitan area of São Paulo 
(SBN 2009). Many recent reports involving Brazilian 
non-profit public clinics have revealed a high prevalence 
of HBV. Ferreira et al. (2006) analysed 1,095 HD patients 
from Goiás and observed that 272 (24.8%) tested posi-
tive against anti-hepatitis B core antibody (anti-HBc) and 
anti-hepatitis B surface antibody (anti-HBs); hepatitis B 
surface antigen (HBsAg) was also detected in 26 of them 
(2.4%). Albuquerque et al. (2009) observed that 29.4% of 
patients under HD from five clinics in Recife (Pernam-
buco, Brazil) tested positive against anti-HBc antibody 
and HBsAg was detected in 3.3% of patients. These au-
thors were in agreement that 54% of patients were either 
positive for HBsAg, HBV DNA or both. The aim of this 
study was to determine the prevalence and the incidence 
of HBV among HD patients and to evaluate whether test-
ing for serological markers at the time of admission is 
suitable for HBV screening in this population.
All patients (n = 123) undergoing treatment in two HD 
centres from March 1997-April 1998 were included in this 
study. The study protocol was submitted and approved by 
the Ethical Committee of Adolfo Lutz Institute and an 
informed consent was obtained from each patient. These 
facilities were considered to be representative of local 
(São Paulo, Brazil) standard HD services. Both units were 
comparable in terms of the budget per subject, presence 
of an isolated area for HBV and HCV patients, recom-
mendation of HBV vaccination for patients and staff and 
isolation of HBsAg-positive patients to the last shift of the 
HBV room. These HD centres had standard conditions 
as determined by Brazilian competent organs and by the 
CDC guidelines, including isolation of HBsAg-positive 
patients in a separate room and assignment of staff mem-
bers to HBsAg-positive patients, but not to HBV-suscepti-
ble patients during the same shift, as well as assignment of 
a supply tray to each patient (CDC 2001, MS 2004).
HD patients had previously received four doses of 
40 µg of Engerix™ B, administered intramuscularly at 
zero, one, two and six months. Once a year, anti-HBs 
is quantified and one dose of vaccine is administered, 
if necessary. Patients had 10 mL of blood drawn from 
arterial-venous fistula just before the HD procedure, at 
the time of admission and on a monthly basis. Therefore, 
a total of 1,476 serum samples were obtained and sepa-
rated into the following three aliquots: serological tests, 
PCR and reconfirmation, if necessary. Samples were 
stored at -20°C in a separate freezer.
The first and the last samples from each patient were 
tested for HBV DNA using DNA extraction and nested 
PCR (core fragment) techniques, as previously described 
(Kaneko et al. 1989). All 1,476 samples were tested for 
HBsAg, total anti-HBc and anti-HBs antibodies using 
commercially available ELISA kits (Hepanostika™ Uni-
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form Organon Teknika BV, Boxtel, Holland). Patients 
who did not present any serological markers at the time 
of admission were referred to receive four doses of the 
HBV vaccine.
Anti-HBc reactivity was observed in 34.1% (CI 95%; 
26.2-42.9) of the patients. HBsAg was detected in 15.4% 
(CI 95%; 9.8-22.6) of the patients and HBV DNA was de-
tected in 8.1% (CI; 4.2-14.01) of this cohort. On the other 
hand, the incidence of HBV infection was zero, mean-
ing that there were no seroconversions during the stud-
ied period. Our findings regarding HBV markers are in 
accordance with previous reports, despite the lack of a 
Brazilian National Survey of HBV infection among HD 
subjects. Souza et al. (2003) observed that 39% of HD pa-
tients from Tocantins, Brazil were positive for anti-HBc, 
while Albuquerque et al. (2009) reported that 29.4% were 
positive for anti-HBc and 3.3% for HBsAg in the North-
eastern Region of Brasil. In the South, the prevalence was 
reported to be 10% for HBsAg and 32.2% for anti-HBc 
(Carrilho et al. 2004). Fabrizi et al. (2008c) reported that 
the prevalence rate of HBsAg detection within dialysis 
units in developing countries remains between 2-20%.
The agreement between HBsAg and HBV DNA was 
about 65%, perhaps due to low viral loads or transient 
detections, as observed by other authors (Fabrizi et al. 
2008c, Tseng et al. 2008). Among the 19 cases that were 
positive for the surface antigen, the molecular method did 
not confirm viral infection in nine (47.3%) of the cases. 
Unfortunately, false positive results were observed in 
three subjects, who were only positive for HBsAg and no 
other serological markers. In two of these cases, HBsAg 
disappeared without anti-HBs seroconversion. Although 
it was not our goal to study occult HBV infections, there 
are no observed cases of this type of infection.
One patient with anti-HBc and anti-HBs reactivity 
manifested fluctuation in HBsAg from negative to posi-
tive in the 2nd, 4th and 7th month. HBV surface antigen 
reactivity has not been shown to be reduced in patients 
undergoing HD treatment and it remains unclear whether 
the procedure contributes to viral reduction in parallel 
(Fabrizi et al. 2008 a, b, Tseng et al. 2008). Our patient, 
however, proved to present a false positive HBsAg result.
HD professional staff may be aware that the relative-
ly high rates of HBV prevalence and the identification 
of transient HBsAg constitute a scenario prone to viral 
transmission. Patients positive for the surface antigen 
are considered HBV carriers and are grouped together 
with other similar cases. However, to avoid false posi-
tive results, one should confirm this result with another 
marker and/or with repeated tests. Therefore, it is highly 
recommended that patients admitted to HD centres be 
subjected to tests for serological HBsAg plus anti-HBc, 
which are economically viable and easy to perform.
Forty-five patients were vaccinated after being ad-
mitted to this study and 17 (37.8%) developed immuno-
logical response with detectable HBs antibody within 12 
months. Although HBV vaccination is mandatory in all 
dialysis units in Brasil, it is possible that it has not been 
adequately implemented. According to the literature, se-
roconversion rates of higher than 60% in HD outpatients 
could be expected (Elwell et al. 2003), but our results were 
below this level. The vaccination may also be followed by 
a transient HBsAg reactivity in HD subjects (Jansen et al. 
1996, Ly et al. 2002). Therefore, it is not recommended to 
test for HBV markers within the first 28 days.
In conclusion, our findings corroborate that HBV is 
prevalent among HD Brasilian patients. As a result, these 
subjects should be screened more often, using at least 
two serological markers at an interval of 2-4 months.
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